🇺🇸 FDA

Intelligence · Patent portfolio

Vertex Pharmaceuticals (Australia) Patents

Full USPTO pharma patent portfolio for Vertex Pharmaceuticals (Australia) — grant dates, expiration, and drug cross-links.

Patents
991
Expiring ≤24m
63

Quick answer

Vertex Pharmaceuticals (Australia) has 991 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 63 expire within 24 months — use filters for patent-cliff planning.

Page 2 of 21

  1. US 11945795

    Islet cell manufacturing compositions and methods of use

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11919887

    Substituted tetrahydrofurans as modulators of sodium channels

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11884672

    Modulators of alpha-1 antitrypsin

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11873300

    Crystalline forms of CFTR modulators

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11866450

    Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11866446

    Inhibitors of APOL1 and methods of using same

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11834441

    Substituted tetrahydrofurans as modulators of sodium channels

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11827627

    N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11813267

    DNA-PK inhibitors

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11807882

    Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11801313

    Materials and methods for treatment of pain related disorders

    Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11801234

    Methods of treating APOL-1 dependent focal segmental glomerulosclerosis

    Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11773119

    Prodrugs of pyridone amides useful as modulators of sodium channels

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11752106

    Pharmaceutical composition and administrations thereof

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11673864

    Pyridone amides as modulators of sodium channels

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11639347

    Modulators of ATP-binding cassette transporters

    Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11634447

    Mannose derivatives for treating bacterial infections

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11623924

    Modulators of alpha-1 antitrypsin

    Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11618746

    Inhibitors of APOL1 and methods of using same

    Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11613744

    Modified urokinase-type plasminogen activator polypeptides and methods of use

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11603351

    Carboxamides as modulators of sodium channels

    Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11591350

    Modulators of cystic fibrosis transmembrane conductance regulator

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11578062

    Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11572364

    Pteridinone compounds and uses thereof

    Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11566236

    Materials and methods for treatment of hemoglobinopathies

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11564916

    Pharmaceutical composition and administrations thereof

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11529337

    Method of treating pain

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11525120

    Stem cell derived islet differentiation

    Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11517564

    Methods of treatment for cystic fibrosis

    Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11485739

    Compounds useful as inhibitors of ATR kinase

    Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11471398

    Devices and methods for delivering therapeutics

    Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11466256

    Stem cell derived islet differentiation

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11464774

    Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11459587

    Materials and methods for treatment of pain related disorders

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11453655

    Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11440907

    Antiproliferation compounds and uses thereof

    Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11426407

    Modulators of cystic fibrosis transmembrane conductance regulator

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11427838

    Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11414439

    Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11390600

    Crystalline forms of C21H22Cl2N4O2

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11370798

    Compounds useful as inhibitors of ATR kinase

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11369692

    Materials and methods for treatment of Duchenne Muscular Dystrophy

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11358977

    Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11345700

    Methods of preparing inhibitors of influenza viruses replication

    Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11291662

    Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11268077

    Materials and methods for treatment of hemoglobinopathies

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11253509

    Methods of treatment for cystic fibrosis

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11203571

    Sulfonamides as modulators of sodium channels

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Vertex Pharmaceuticals (Australia) have?

991 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Vertex Pharmaceuticals (Australia) patents expire?

63 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.